Basic↦Quality and Risk↦Risk-Based Approach to Quality↦Risk Evaluation and Prioritisation
What is it? Why is it important?
Risk evaluation includes to assess the significance of identified study risks, such as:
- The likelihood or frequency that a risk occurs
- The detectability or ability to identify a risk in a timely manner
- The expected impact of a risk on the integrity of study defined Critical to Quality (CtoQ) factors (e.g. low, medium, high impact)
- The rating of the risk based on how difficult, how likely, or how easy can the risk be detected
Risk prioritisation includes to decide which risks matter most, such as:
- To set risk priorities based on risk evaluation
- How will risk-priority affect the implementation of risk control-measures and the investment of resources, such as:
- Adaptations in monitoring intensity and frequency, with higher priority risks receiving more robust oversight
- Required adaptations in trial conduct to minimize participant burden while guaranteeing data quality
Both the SP-INV (i.e on study level) and Site-INV(s) (i.e. on site level) are responsible to evaluate and prioritize risks threatening CtoQ factors.
What do I need to do?
As a SP-INV or Site-INV evaluate and prioritise identified study risks, consider:
- The frequency and detectability of potential errors
- The potential impact on the study`s CtoQ factors (e.g. participant right and safety, data quality)
- The evolving risk profile throughout the trial lifecycle, and plan procedures for the periodic reassessment of study risks, including the efficacy and applicability of implemented risk control-measures
Apply these principles by using:
- A Quality by Design (QbyD) approach, with the aim to manage risks before they occur, thereby providing credible and useful study results
- A Risk Evaluation Matrix (REM) or other risk assessment tool to:
- Regularly check risk impact on the study`s CtoQ factors
- Set clear priorities for actions to reduce risks and monitor trial activities
- Apply quality control measures proportionate to risk level
- Work as a multidisciplinary team to continuously review risks and respond in a timely way
Where can I get help?
Your local Research Support Centre↧ can assist you with experienced staff regarding this topic
Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch
Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch
Bern, Department of Clinical Research (DCR), dcr.unibe.ch
Geneva, Clinical Research Center (CRC), crc.hug.ch
Lausanne, Clinical Research Center (CRC), chuv.ch
St. Gallen, Clinical Trials Unit (CTU), h-och.ch
Zürich, Clinical Trials Center (CTC), usz.ch
References
ICH GCP E6(R3) – see in particular guidelines
- 3.10 Quality management
- 3.10.1.2 Risk evaluation
- 3.10.1.6 Risk review
ICH E8(R1) – see in particular
- 3.1 Quality by Design of clinical studies
- 3.2 Critical to Quality Factors
ISO 31000 (access liable to costs) – see in particular section
- Risk management: Principles and guidelines